Magnifying Glass
Search Loader

Peter L. Bonate & Danny R. Howard 
Pharmacokinetics in Drug Development 
Advances and Applications, Volume 3

Support
Adobe DRM
Cover of Peter L. Bonate & Danny R. Howard: Pharmacokinetics in Drug Development (PDF)

The topics chosen for this volume were selected because they are some of the current development or technological issues facing drug development project teams.  They regard the practical considerations for assessment of selected special development populations.  For example, they include characterization of drug disposition in pregnant subjects, for measuring arrhythmic potential, for analysis tumor growth modeling, and for disease progression modeling.  Practical considerations for metabolite safety testing, transporter assessments, Phase 0 testing, and development and execution of drug interaction programs reflect current regulatory topics meant to address enhancement of both safety assessment and early decision-making during new candidate selection.  Important technologies like whole body autoradiography, digital imaging and dried blood spot sample collection methods are introduced, as both have begun to take a more visible role in pharmacokinetic departments throughout the industry. 

€213.99
payment methods

Table of Content

Preface


1.    Modeling Tumor Growth in Oncology


Peter L. Bonate


2.    Drug-Drug Interactions: Designing Development Programs and Appropriate Product Labeling


J. Matthew Hutzler, Jack Cook, and Joseph C. Fleishaker


3.    Modeling the Progression of Disease


Diane R. Mould


4.    The Use of Dried Blood Spots for Concentration Assessment in Pharmacokinetic Evaluations


Tapan K. Majumdar and Danny R. Howard


5.    Microdosing: Pharmacokinetic and Metabolism Data Early in the Drug Development Process


Graham Lappin


6.    Metabolite Testing in Drug Development


Angus N. R. Nedderman and Don K. Walker


7.    The –Omics in Drug Development


Majid Y. Moridani, Robyn P. Araujo, Caroline H. Johnson, and John C. Lindon


8.    Optimal Design of Pharmacokinetic-Pharmacodynamic Studies


Lee-Kien Foo and Stephen B. Duffull


9.    Pharmacokinetic Studies in Pregnant Women


Jamie L. Renbarger and David M. Haas


10.  Design, Conduct and Analysis of Thorough QT Studies


Tanya Russell, Daniel S. Stein, and David J. Kazierad


11.  Contribution of Quantitative Whole-body Autoradioluminography to the Early Selection and Development of Drug Candidates


Alain Schweitzer


12.  Pharmacokinetics, Modeling, and Simulation in the Development of Sunitinib Malate: A Case Study


Brett E. Houk and Carlo L. Bello


13.  The Clinical Significance of Drug Transporters in Drug Disposition and Drug Interactions


Thomas N. Thompson

About the author

Peter Bonate has 16 years industrial experience, 13 years as a clinical pharmacologist/pharmacokineticist and 3 years in drug metabolism and bioanalysis.  He is currently a Director in the Clinical Pharmacology, Modeling, and Simulation department at Glaxo Smith Kline in the oncology therapeutic area.   He has also worked at Genzyme, Hoechst Marion Roussel, Eli Lilly, and Quintiles.  He received his Ph.D. in 1996 from Indiana University in Medical Neurobiology with an emphasis on the pharmacokinetics of drugs of abuse.  He received an MS in statistics from the University of Idaho and an MS in Pharmacology from Washington State University both in 1990.  In 2003 he was elected a Fellow of the American College of Clinical Pharmacology and in 2007 was elected a fellow of the American Association of Pharmaceutical Scientists (AAPS).  He was founder of the Modeling and Simulation focus group, has served as chair of the population pharmacokinetics focus group, and was section leader for the Clinical Pharmacology and Translational Research Section within AAPS.  He has served or currently serves on the editorial boards for the Journal of Clinical Pharmacology, Pharmaceutical Research, Journal of Pharmacokinetics and Pharmacodynamics, and the AAPS Journal.  He has more than 40 publications in the field of pharmacokinetics and clinical pharmacology, is co-editor of the 2-volume series Pharmacokinetics in Drug Development published by AAPS Press in 2004, and is author of the book Pharmacokinetic-Pharmacodynamic Modeling and Simulation  published by Springer in 2005.
 
Danny Howard received his Bachelor’s of Science degree in Pharmacy, and Ph.D. from the University of Missouri in Kansas City.  He began working in the pharmaceutical industry in 1991, first as a biopharmaceutics consultant and then as pharmaceutical scientist for Marion Merrell Dow, Hoechst Marion Roussel, Aventis, and Quintiles.  He is currently the Vice President of Global Pharmacokinetics and Pharmacodynamics for Novartis.  His career has included responsibilities in both clinical and nonclinical pharmacokinetics and pharmacodynamics, bioanalytics, and pharmaceutical business operations. He has worked with numerous drug submissions supporting both large and small molecules worldwide.  He was a charter member of the Missouri Biotech Association and served as its first Board Chairman.  With Peter Bonate, he was the co-editor of the series
Pharmacokinetics in Drug Development published by AAPS Press in 2004.  
Language English ● Format PDF ● Pages 319 ● ISBN 9781441979377 ● File size 7.0 MB ● Editor Peter L. Bonate & Danny R. Howard ● Publisher Springer US ● City NY ● Country US ● Published 2011 ● Downloadable 24 months ● Currency EUR ● ID 2150540 ● Copy protection Adobe DRM
Requires a DRM capable ebook reader

More ebooks from the same author(s) / Editor

8,868 Ebooks in this category